Mechanism and strategy for treatment of cancer metastasis to bone

Japanese Journal of Cancer and Chemotherapy

Volumn 38, Issue 6, 2011, Pages 877-884

  Yoneda, Toshiyuki ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Bisphosphonates; Bone resorption; Osteoclasts; RANKL RANK

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; NEUTRALIZING ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE RELATED PROTEIN;

APOPTOSIS; BONE METASTASIS; CANCER CELL; CANCER PATIENT; DRUG EFFICACY; DRUG MECHANISM; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; OSTEOCLAST; OSTEOLYSIS; REVIEW;

EID: 84866998711     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Mundy GR: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2: 584-593, 2002.
2. Paget S: The distribution of secondary growths in cancer of the breast. Lancet 1: 571-573, 1889.
3. Hauschka PV, Mavrakos AE, Iafrati MD, et al: Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin sepharose. J Biol Chem 261: 12665-12674, 1986. (Pubitemid 17204223)
4. Yoneda T, Sasaki A and Mundy GR: Osteolytic bone disease in breast cancer. Breast Cancer Res Treat 32: 73-84, 1994. (Pubitemid 24322250)
5. Sela J: Bone remodeling in pathological conditions. Calcf Tiss Res 23: 229-234, 1977.
6. Boyde A, Maconnachie E, Reid SA, et al: Scanning electron microscopy in bone pathology: Review of methods, potential and applications. Scanning Electron Microscopy 4: 1537-1554, 1986. (Pubitemid 17224036)
7. Coleman RE: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12: 6243s-6249s, 2006.
8. Kearns AE, Khosla S and Kostenuik PJ: Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 29: 155-192, 2008. (Pubitemid 351519689)
9. Yoneda T and Hiraga T: Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun 328: 679-687, 2005. (Pubitemid 40208305)
10. Guise TA, Yin JJ, Taylor SD, et al: Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 98: 1544-1549, 1996. (Pubitemid 26327863)
11. Hiraga T, Myoui A, Choi ME, et al: Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor β enhances bone metastases in breast cancer. Cancer Res 66: 2067-2073, 2006.
12. Hiraga T, Kizaka-Kondoh S, Hirota K, et al: Hypoxia and HIF-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res 67: 4157-4163, 2007. (Pubitemid 46815061)
13. Yoneda T, Williams PJ, Hiraga T, et al: A bone-seeking subclone exhibits different properties from the parental MDA-MB-231 human breast cancer cells and a brain-seeking subclone in vivo and in vitro. J Bone Miner Res 16: 1486-1495, 2001. (Pubitemid 32675200)
14. Tamura D, Hiraga T, Myoui A, et al: Cadherin-11-mediated interactions with bone marrow stromal/osteoblastic cells support selective colonization of breast cancer cells in bone. Int J Oncol 33: 17-24, 2008.
15. Cabodi S, del Pilar Camacho-Leal M, Di Stefano P, et al: Integrin signalling adaptors: not only figurants in the cancer story. Nat Rev Cancer 10: 858-870, 2010.
16. Hollier BG, Evans K and Mani SA: The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies. J Mammary Gland Biol Neoplasia 14: 29-43, 2009.
17. Lévesque JP, Helwani FM and Winkler IG: The endosteal 'osteoblastic' niche and its role in hematopoietic stem cell homing and mobilization. Leukemia 24: 1979-1992, 2010.
18. Deal C: Potential new drug targets for osteoporosis. Nat Clin Pract Rheumatol 5: 20-27, 2009.
19. Neville-Webbe HL and Coleman RE: Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease. Eur J Cancer 46: 1211-1222, 2010.
20. Gnant M, Mlineritsch B, Schippinger W, et al: Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360: 679-691, 2009.
21. Hiraga T, Williams PJ, Ueda A, et al: Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 10: 4559-4567, 2004. (Pubitemid 38878900)
22. Chlebowski RT, Chen Z, Cauley JA, et al: Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol 28: 3582-3590, 2010.
23. Yoneda T, Hagino H, Sugimoto T, et al: Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Osteoporosis Society Japan, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology and Japanese Society of Oral and Maxillofacial Surgeons. J Bone Miner Metab 28: 365-383, 2010.
24. Blair JM, Zhou H, Seibel MJ, et al: Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. Nat Clin Pract Oncol 3: 41-49, 2006. (Pubitemid 43108833)
25. Lipton A, Steger GG, Figueroa J, et al: Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 25: 4431-4437, 2007. (Pubitemid 350013849)
26. Smith MR, Egerdie B, Hernández Toriz N, et al: Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361: 745-755, 2009.
27. Stopeck AT, Lipton A, Body JJ, et al: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28: 5132-5139, 2010.
28. Lipton A, Siena S, Rader M, et al: Comparison of denosumab versus zoledronic acid for treatment of bone metastases in advanced cancer patients: An integrated analysis of 3 pivotal trials. ECCO/ESMO abstr 1249, 2010.
29. Henry D, Costa L, Goldwasser F, et al: A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29: 1125-1132, 2011.
30. Coleman RE: Skeletal complications of malignancy. Cancer 80: 1588-1594, 1997.
31. Schulman KL and Kohles J: Economic burden of metastatic bone disease in the U. S. Cancer 109: 2334-2342, 2007. (Pubitemid 46801565)
32. Vallet S, Smith MR and Raje N: Novel bone-targeted strategies in oncology. Clin Cancer Res 16: 4084-4093, 2010.
33. Yoneda T, Michigami T, Yi B, et al: Actions of bisphosphonate on bone metastasis in animal models of breast cancer. Cancer 88: 2979-2988, 2000. (Pubitemid 30413180)